EN
HI
Concord Drugs Chart
Concord Drugs Share Key Metrics
Volume
11019.00
Market Cap
107.55 CR
LTQ@LTP
25@83.93
ATP
84.03
Var Margin
25 %
Circuit Range
73.47-89.79
Delivery %
83.29 %
Value
9.26 L
ASM/GSM
No
Market Lot
1
Summary
Concord Drugs share price is ₹83.93 as of 29 May, 2026. The stock Concord Drugs intraday movement has stayed between ₹81.10 and ₹86.00, while on a 52-week basis,Concord Drugs price 52 week high is ₹92.52 & its 52 week low is ₹29.00.
In terms of trading activity, Concord Drugs has recorded a volume of 11019 shares, The Concord Drugs has a market cap of ₹13175000 CR. The stock’s Average Traded Price (ATP) stands at ₹84.03, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 25 @ ₹83.93.
Concord Drugs operates within a circuit range of ₹73.47 – ₹89.79, with a Value of ₹9.26 L. The Delivery Percentage for the day is 83.29%. Additionally, Concord Drugs currently falls under the No framework, and trades with a market lot size of 1.
Concord Drugs Fundamentals
View MoreP/E Ratio
101.94
P/B Ratio
2.22
Div. Yield
0
Sector P/E
55.51
Sector P/B
3.01
Sec. Div. Yield
0.55
Concord Drugs Resistance and Support
Pivot 82.25
Resistance
First Resistance
86.39
Second Resistance
91.14
Third Resistance
95.28
Support
First Support
77.5
Second Support
73.36
Third Support
68.61
Concord Drugs Corporate Actions
| Date | Agenda |
|---|---|
| 2026-05-27 | Audited Results |
| 2026-02-14 | Quarterly Results |
| 2025-11-13 | Quarterly Results |
| 2025-08-08 | Quarterly Results |
| 2025-07-03 | Preferential issue of shares |
| 2025-06-27 | Preferential Issue of shares & Others |
| 2025-05-23 | Audited Results |
| 2025-03-17 | Preferential Issue of shares & Others |
| 2025-03-13 | Preferential Issue of shares & Others |
| 2025-01-11 | Quarterly Results |
Concord Drugs News
Concord Drugs Ltd - 538965 - Board Meeting Outcome for Approval Of Financial Results
Concord Drugs announced audited FY26 cons. financial results, with revenue up 74% YoY to ₹78.77 crores and net profit up 213% to ₹1.05 crores. Auditors noted ₹4.14 crore long-outstanding trade receivables without bad debt provision.
May 27 2026 16:32:33
Concord Drugs Ltd - 538965 - Board Meeting Intimation for Audited Results For Year Ending 31.03.2026
Concord Drugs Ltd will hold a board meeting on May 27, 2026. The agenda includes considering and approving the audited financial results for the year and quarter ended March 31, 2026.
May 18 2026 18:38:30
Concord Drugs Management
| Name | Position |
|---|---|
| S Nagi Reddy | Chairman & Managing Director |
| S Koni Reddy | Whole Time Director & Chief Financial Officer |
Concord Drugs Similar Stocks
Raaj Medisafe India Ltd.
88.01
-1.00 (1.12%)
Mercury Laboratories Ltd.
763.45
-3.55 (0.46%)
Bharat Immunologicals & Biologicals Corporation Ltd.
17.50
-0.23 (1.30%)
Fortis Malar Hospitals Ltd.
53.90
-1.30 (2.36%)
Everest Organics Ltd.
267.80
7.80 (3.00%)
Astal Laboratories Ltd.
73.95
-0.08 (0.11%)
Makers Laboratories Ltd.
163.75
-3.05 (1.83%)
Pharmaids Pharmaceuticals Ltd.
30.34
2.59 (9.33%)
Concord Drugs FAQs
The Buying Price of Concord Drugs share is 83.93 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.
To buy Concord Drugs stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Concord Drugs, choose your preferred order type, and place the trade.
The Price-to-earnings (P/E) ratio of Concord Drugs shares is 101.94. You can compare it with the sector average for relative valuation.
The Price to Book (P/B) ratio Concord Drugs shares is 2.22. Useful to assess the stock's value relative to its book value.
To assess Concord Drugs’s valuation compare Sector P/E, P/B which are 55.51 & 3.01 with sector averages, along with growth rates and financial metrics.
The Market Cap of Concord Drugs is 107.55 CR. It indicates the company's size category and trading liquidity.
The 52 week high and low prices of Concord Drugs share price is 92.52 & 29.00. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.
Concord Drugs belongs to the Healthcare sector.
